Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2021
Fined approximately 764 million yuan for drug resale price monopoly
In April 2021, the State Administration for Market Regulation determined that Yangtze River Pharmaceutical Group implemented monopoly agreements from 2015 to 2019 to fix and set minimum resale prices for drugs, eliminating and restricting market competition, and imposed a fine of approximately 764 million yuan.
2021
China's market regulator fines Yangtze River Pharmaceutical Group
Fine or penalty
China's State Administration for Market Regulation fined Yangtze River Pharmaceutical Group 764 million yuan and ordered it to stop the conduct. The regulator found that the group had reached agreements with downstream businesses to fix or set minimum resale prices for medicines, excluding and restricting competition and harming consumers' legitimate rights and interests and the public interest.
Source excerpt
扬子江药业集团上述行为排除、限制了竞争，损害了消费者合法权益和社会公共利益，违反《反垄断法》第十四条“禁止经营者与交易相对人达成下列垄断协议：(一)固定向第三人转售商品的价格；(二)限定向第三人转售商品的最低价格”的规定。
2021年4月15日，市场监管总局根据《反垄断法》第四十六条、四十九条规定作出行政处罚决定，责令扬子江药业集团停止违法行为，并处以其2018年销售额254.67亿元3%的罚款，计7.64亿元。
2019
Commercial bribery case
Chinese market regulators penalized Yangtze River Pharmaceutical in a case involving commercial bribery practices connected with pharmaceutical promotion and sales. The case formed part of broader Chinese enforcement against improper marketing and healthcare-sector bribery. The event is included as a regulatory and reputational matter; the exact legal characterization and penalty details should be confirmed from the regulator’s original decision.